CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.

Laura E JansenWendy A TeftRhiannon V RoseDaniel J LizotteRichard B Kim

Published in: Breast cancer research and treatment (2018)

Hot flash severity during tamoxifen therapy can not be accounted for by CYP2D6 genotype or observed plasma concentration of tamoxifen, 4-hydroxytamoxifen, or endoxifen.

Keyphrases

breast cancer cells
estrogen receptor
positive breast cancer
stem cells
mesenchymal stem cells
cell therapy